– Detailed results from the CENTERSTONE trial show treatment with Xofluza reduced the odds of transmission, or spread of influenza virus, from an infected person to household members by 32% – – ...
– Genentech’s new program will provide access to Xofluza through select pharmacies with a $50 cash pay option, 70 percent lower than the list price – – Direct-to-patient program focuses on same day ...
The FDA approved the biotechnology company Genentech’s Xofluza drug to treat children aged 5-12 with influenza. Xofluza is the first single-dose influenza drug approved by the FDA to treat children in ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the Phase III CENTERSTONE trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results